Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications

• US 20050227249A1
• Filed: 10/14/2004
• Published: 10/13/2005
• Est. Priority Date: 07/30/1999
• Status: Abandoned Application

• Current Assignee: Transgenomic, Inc. (Precipio, Inc.)
• Original Assignee: Transgenomic, Inc. (Precipio, Inc.)
• Inventors: Brinkmann, Ulrich, Roots, Ivar, Eichelbaum, Michel, Hoffmeyer, Sven
• Application Number:
  US10/965,348
• Publication Number:
  US 20050227249A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the Multi Drug Resistance-1 (MDR-1) gene. In particular, polynucleotides of molecular variant MDR-1 genes which, for example, are associated with unsufficient and/or altered uptake of drugs by a target cell, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant MDR-1 proteins are described. In addition, variant MDR-1 proteins and antibodies specifically recognizing such proteins as well as concerns transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the MDR-1 gene as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors, proteins, antibodies and inhibitors by the above-described method are provided. Said compositions are particularly useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the MDR-1 gene product.

Claims

1-45. -45. (canceled)

46. A method of diagnosing acquired multidrug resistance or sensitivity related to the presence of a molecular variant of the MDR-1 gene comprising determining in a sample from a subject the presence of a polynucleotide selected from the group consisting of:

(a) a polynucleotide having the nucleic acid sequence of SEQ ID NO 122;

(b) a polynucleotide encoding a molecular variant Multi Drug Resistance (MDR)-1 polypeptide, wherein said polynucleotide is having at a position corresponding to position 176 of the MDR-1 gene (Accession No;

M29445 or J05168) a nucleotide exchange;

(c) a polynucleotide encoding a molecular variant MDR-1 polypeptide, wherein said polynucleotide is having at a position corresponding to position 176 of the MDR-1 gene (Accession No;

M29445 or J05168) a T; and

(d) a nucleic acid molecule complementary to the polynucleotide of (a) to (c);

wherein the presence of said polynucleotide is considered indicative of said acquired multidrug resistance or sensitivity in said method.

47. The method of claim 46, wherein the nucleotide substitution results in altered expression of the variant MDR-1 gene compared to the corresponding wild type gene.

48. The method of claim 46, wherein said acquired multidrug resistance is in tumors and other diseases, the therapy of which is dependent on drug treatment.

49. The method of claim 47, wherein said acquired multidrug resistance is in tumors and other diseases, the therapy of which is dependent on drug treatment.

52. The method of any one of claims 46 to 51, comprising PCR, ligase chain reaction, restriction digestion, direct sequencing, nucleic acid amplification techniques, hybridization techniques or immunoassays.

53. The method of any one of claims 46 to 51, wherein an oligo- or polynucleotide is used for diagnosing acquired multidrug resistance or sensitivity related to the presence of a molecular variant of the MDR-1 gene.

54. The method of claim 52, wherein an oligo- or polynucleotide is used for diagnosing acquired multidrug resistance or sensitivity related to the presence of a molecular variant of the MDR-1 gene.

55. The method of claim 53, wherein said oligonucleotide is about 15 to 50 nucleotides in length and comprises the nucleotide sequence of SEQ ID NOs 122 or a complementary sequence of any one of those.

56. The method of claim 54, wherein said oligonucleotide is about 15 to 50 nucleotides in length and comprises the nucleotide sequence of SEQ ID NOs 122 or a complementary sequence of any one of those.

60. A diagnostic composition comprising the primer or probe as defined in claim 53.

61. A diagnostic composition comprising the primer or probe as defined in claim 54.

50. A method of diagnosing a disorder related to the presence of a molecular variant of the MDR-1 gene or susceptibility to such a disorder, comprising determining in a sample from a subject the presence of a polynucleotide selected from the group consisting of:

(a) a polynucleotide having the nucleic acid sequence of SEQ ID NO 122;

(b) a polynucleotide encoding a molecular variant Multi Drug Resistance (MDR)-1 polypeptide, wherein said polynucleotide is having at a position corresponding to position 176 of the MDR-1 gene (Accession No;

M29445 or J05168) a nucleotide exchange;

(c) a polynucleotide encoding a molecular variant MDR-1 polypeptide, wherein said polynucleotide is having at a position corresponding to position 176 of the MDR-1 gene (Accession No;

M29445 or J05168) a T; and

(d) a nucleic acid molecule complementary to the polynucleotide of (a) to (c);

wherein the presence of said polynucleotide is considered indicative of said acquired multidrug resistance or sensitivity in said method.

51. The method of claim 50, wherein said disorder is cancer.

57. A method for the prediction of blood levels of a MDR-1 substrate and/or inducer for improvement of drug safety and efficacy, to predict and prevent side effects and drug interactions and/or to increase patient compliance comprising using a MDR-1 gene single nucleotide polymorphism (SNP) MDR-1 in exon 26 (C3435T) as a pharmacogenetic factor.

58. The method of claim 57, wherein the substrate and/or inducer are selected from anticonvulsant/antiepileptic drugs, cardiac glycosides, immunosuppressive drugs, macrolid-antibiotics, or macrocyclic-antibiotics.

59. A diagnostic composition comprising a polynucleotide selected from the group consisting of:

(a) a polynucleotide having the nucleic acid sequence of SEQ ID NO 122;

(b) a polynucleotide encoding a molecular variant Multi Drug Resistance (MDR)-1 polypeptide, wherein said polynucleotide is having at a position corresponding to position 176 of the MDR-1 gene (Accession No;

M29445 or J05168) a nucleotide exchange;

(c) a polynucleotide encoding a molecular variant MDR-1 polypeptide, wherein said polynucleotide is having at a position corresponding to position 176 of the MDR-1 gene (Accession No;

M29445 or J05168) a T; and

(d) a nucleic acid molecule complementary to the polynucleotide of (a) to (c).